Literature DB >> 21173754

Vasculitis: Rituximab: effective in ANCA-associated vasculitis?

Ulf Schönermarck, Kirsten de Groot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21173754     DOI： 10.1038/nrneph.2010.167

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis.

Authors:  Michael Walsh; Peter A Merkel; Alfred Mahr; David Jayne
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

4.  B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions.

Authors:  J Voswinkel; A Mueller; J A Kraemer; P Lamprecht; K Herlyn; K Holl-Ulrich; A C Feller; S Pitann; A Gause; W L Gross
Journal:  Ann Rheum Dis       Date:  2005-11-16       Impact factor: 19.103

5.  A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Rachel B Jones; Alastair J Ferraro; Afzal N Chaudhry; Paul Brogan; Alan D Salama; Kenneth G C Smith; Caroline O S Savage; David R W Jayne
Journal:  Arthritis Rheum       Date:  2009-07

6.  Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.

Authors:  Ronald F van Vollenhoven; Paul Emery; Clifton O Bingham; Edward C Keystone; Roy Fleischmann; Daniel E Furst; Katherine Macey; Marianne Sweetser; Ariella Kelman; Ravi Rao
Journal:  J Rheumatol       Date:  2010-01-28       Impact factor: 4.666

7.  Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis.

Authors:  Mark A Little; Peter Nightingale; C A Verburgh; Thomas Hauser; Kirsten De Groot; Caroline Savage; David Jayne; Lorraine Harper
Journal:  Ann Rheum Dis       Date:  2009-07-01       Impact factor: 19.103

8.  Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

Authors:  Kirsten de Groot; Lorraine Harper; David R W Jayne; Luis Felipe Flores Suarez; Gina Gregorini; Wolfgang L Gross; Rashid Luqmani; Charles D Pusey; Niels Rasmussen; Renato A Sinico; Vladimir Tesar; Philippe Vanhille; Kerstin Westman; Caroline O S Savage
Journal:  Ann Intern Med       Date:  2009-05-19       Impact factor: 25.391

9.  Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis.

Authors:  Oliver M Steinmetz; Joachim Velden; Ursula Kneissler; Marlies Marx; Antje Klein; Udo Helmchen; Rolf A K Stahl; Ulf Panzer
Journal:  Kidney Int       Date:  2008-06-04       Impact factor: 10.612

10.  B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.

Authors:  M Martinez Del Pero; A Chaudhry; R B Jones; P Sivasothy; P Jani; D Jayne
Journal:  Clin Otolaryngol       Date:  2009-08       Impact factor: 2.597
  10 in total
  1 in total

1.  Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone.

Authors:  Evgeniy Evdoshenko; Alexey Maslyanskiy; Sergey Lapin; Leonid Zaslavsky; Ruth Dobson; Areg Totolian; Alexander Skoromets; Amit Bar-Or
Journal:  ISRN Neurol       Date:  2013-09-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.